DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Moderna is now expecting 2025 research and development costs of about $4.1 billion and selling, general and administrative costs of about $1.1 billion. Cost of sales is expected to come to about $1.2 ...

Super Micro Computer rises sharply, Nvidia sells its stake in SoundHound, Airbnb swings to a profit in the fourth quarter, and Moderna posts a wider-than-expected quarterly loss.

Moderna Inc. recorded a quarterly loss as vaccine sales waned and the company had an unexpected charge for a canceled ...

Wolfe Research lowered the firm’s price target on Moderna (MRNA) to $25 from $35 and keeps an Underperform rating on the shares. The firm ...

Ray Dalio’s Bridgewater Associates, which is one of the world’s largest hedge funds, made significant adjustments to its ...

Welcome to the Moderna fourth quarter 2024 conference call. At this time, all participants are in a listen-only mode. After ...

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

The Dow Jones Industrial Average shed 165.35 points, or 0.37%, closing at 44,546.08. The S&P 500 ticked down 0.01% to ...

The Dow Jones Industrial Average ( ^DJI) added more than 0.7%, or over 350 points, while the S&P 500 ( ^GSPC) put on over 1% ...

Vaccine maker Moderna had no Valentine’s Day chocolates for investors when its financial results came out Friday. The company ...

Moderna (MRNA) delivered earnings and revenue surprises of 7.06% and 1.04%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?